Pao Group Stock Price, News & Analysis

On October 19, 2021, PAO Group announced the launch of its first CBD nutraceutical product, RelaxRX CBD, intended as a sleep aid. The company plans to introduce a second product on October 21, 2021, and anticipates generating its first revenue in Q4 2021 after acquiring intellectual property related to CBD extraction. PAOG has confirmed the shipping of its products to North American Cannabis Holdings, which will sell them online. The company expects to grow revenue significantly with follow-on products lined up for launch.

PAO Group, Inc. (OTC Pink: PAOG) has launched its first CBD nutraceutical product, RelaxRX CBD, aimed at promoting better sleep. The company plans to introduce a second product shortly. PAOG anticipates generating its first revenue in Q4 2021, thanks to a patented extraction method (U.S. Patent No. 9,199,960) for CBD. The initial products have been shipped to North American Cannabis Holdings, Inc. (OTC Pink: USMJ) for online sales. PAOG expects rapid revenue growth from upcoming product launches.

PAO Group, Inc. (OTC Pink: PAOG) announced the launch of its first CBD nutraceutical product, RelaxRX CBD, a sleep aid. Available in 30mg Softgels and an 1800mg Tincture, the product is made from 100% full spectrum whole plant hemp oil. The sleep aid market is projected to grow from USD 64.29 Billion in 2019 to USD 101.7 Billion by 2026. PAOG has shipped RelaxRX to its distribution partner, North American Cannabis Holdings, Inc. (OTC Pink: USMJ), with sales expected online soon. The company anticipates rapid revenue growth following this launch.

PAO Group, Inc. (OTC Pink: PAOG) has commenced shipping its first CBD nutraceutical product to North American Cannabis Holdings, Inc. (OTC Pink: USMJ). This marks a significant step as PAOG prepares for a formal product launch on October 18, 2021. The CBD market is projected to reach $100 billion, and PAOG anticipates rapid revenue growth from this initial offering and follow-on products. The company has previously acquired intellectual property from research on a patented CBD extraction method (U.S. Patent No. 9,199,960), enabling development of both pharmaceutical and nutraceutical treatments.

PAO Group, Inc. (OTC Pink: PAOG) is launching its first CBD nutraceutical product on October 18, 2021, expecting to generate its first sales in Q4, 2021. The company has begun shipping this product to its distribution partner, North American Cannabis Holdings, Inc. (OTC Pink: USMJ). PAOG anticipates rapid revenue growth following this launch, with additional products planned. The company utilizes a patented cannabis extraction method to develop its CBD pharmaceuticals and nutraceuticals. The CBD nutraceutical market, valued at $5.2 billion, is expected to reach $16.4 billion by 2027.

PAO Group, Inc. (OTC Pink: PAOG) has garnered significant outside interest in its CBD pharmaceutical respiratory treatment research. The company owns intellectual property related to CBD and is developing a product named RespRx. Engaging Veristat as a CRO, PAOG is preparing an IND for FDA approval. Anticipating its first CBD nutraceutical product sales in Q4 2021, the company plans to announce product specifics soon. With the CBD nutraceuticals market projected to grow from $5.2 billion in 2020 to $16.4 billion by 2027, PAOG expects rapid revenue growth following the product launch.

PAO Group, Inc. (OTC Pink: PAOG) announced plans to begin sales of its first CBD nutraceutical product in Q4 2021, following a deal with North American Cannabis Holdings, Inc. (OTC Pink: USMJ). The company anticipates rapid revenue growth with additional products following the initial launch. PAOG's CBD products are developed using its patented cannabis extraction method. The 2020 CBD nutraceuticals market was valued at $5.2 billion and is projected to grow to $16.4 billion by 2027, indicating significant market potential for PAOG's offerings.

PAO Group, Inc. (OTC Pink: PAOG) has shipped its first CBD nutraceutical product to a distribution partner, marking its entry into the CBD market. This development stems from the company’s patented cannabis extraction method (U.S. Patent No. 9,199,960). The CBD nutraceuticals market was valued at $5.2 billion in 2020 and is projected to reach $16.4 billion by 2027. PAOG anticipates generating its first revenue in 2021. Further specifics on the product will be announced upon the distribution setup with North American Cannabis Holdings (OTC Pink: USMJ).

PAO Group, Inc. (OTC PINK: PAOG) is pursuing merger and acquisition opportunities to expand its product line and enhance revenue growth. The company has commenced production of its first line of CBD nutraceuticals and is on track to generate revenue this year. PAOG is leveraging its patented cannabis extraction method to develop CBD pharmaceuticals and nutraceuticals. The CBD nutraceuticals market was valued at $5.2 billion in 2020 and is projected to reach $16.4 billion by 2027. Distribution will occur through North American Cannabis Holdings, Inc. (OTC Pink: USMJ).